Overview

Uniform Multidrug Therapy Regimen for Leprosy Patients

Status:
Completed
Trial end date:
2016-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this randomized trial is to verify if leprosy patients, despite of their classification, can be treated with the same regimen without compromising patient cure and acceptability of the treatment. At present, patients classified as multibacillary leprosy are treated for 12 months with three drugs, and patients classified as paucibacillary leprosy are treated for 6 months with two drugs. The study is going to test a unified regimen for paucibacillary and multibacillary patients by treating leprosy patients with three drugs for 6 doses.
Phase:
Phase 4
Details
Lead Sponsor:
University of Brasilia
Collaborators:
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Fundação Alfredo da Matta, Manaus, Brazil
Instituto de Dermatologia Dona Libania, Fortaleza, Brazil
Ministry of Health, Brazil
Ministry of Science and Technology, Brazil
Treatments:
Clofazimine
Dapsone
Rifampin